about
Use of Contraception and Attitudes towards Contraceptive Use in Swedish Women--A Nationwide Survey.Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis.Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.Use of effective contraception 6 months after emergency contraception with a copper intrauterine device or ulipristal acetate - a prospective observational cohort study.Persistence of Lactobacilli in Postmenopausal Women - A Double-Blind, Randomized, Pilot Study.The efficacy, safety and acceptability of medical termination of pregnancy provided by standard care by doctors or by nurse-midwives: a randomised controlled equivalence trial.Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.Transurethral Polyacrylamide Hydrogel Injection Therapy in Women Not Eligible for Midurethral Sling Surgery.Perfect-use and typical-use Pearl Index of a contraceptive mobile app.Cost of unintended pregnancy in Sweden - a possibility to lower costs by increasing LARC-usage.Clarifications concerning contraceptive mobile app Pearl Index calculations.Imaging single DNA molecules for high precision NIPT.Contraception following abortion and the treatment of incomplete abortion.Investigating the loss of work productivity due to symptomatic leiomyoma.Benefits of reversible contraception.Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trialLateral episiotomy versus no episiotomy to reduce obstetric anal sphincter injury in vacuum-assisted delivery in nulliparous women: study protocol on a randomised controlled trialEffect of letrozole on uterine tonus and contractility: a randomized controlled trialRisk of abortion within 1-2 years after childbirth in relation to contraceptive choice: a retrospective cohort studyContraceptive use at the time of and after an ectopic pregnancy: a retrospective cohort studyInsertion experience of women and health care professionals in the Kyleena® Satisfaction StudyLevonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancyEfficacy of mifepristone and misoprostol for medical treatment of missed miscarriage in clinical practice-A cohort studyIntrauterine mepivacaine instillation for pain relief during intrauterine device insertion in nulliparous women: a double-blind, randomized, controlled trialUrodynamics as a Prognosticator of Mirabegron Treatment OutcomesTrends in use and attitudes towards contraception in Sweden: results of a nationwide surveyShort- and long-term effect of contraceptive methods on fecundity
P50
Q35629286-4914D02E-8A47-401D-A448-A40F70C06009Q36064773-7435E055-5691-4905-9C32-7CFD890F22C8Q37695965-F76DE094-8818-479D-8581-63580F07E186Q38876684-966FF817-C495-4249-B3D7-04C95C866F84Q38885390-AD065D56-9EB2-44A5-BD00-5C3C80472367Q39157349-33FF1271-A3E6-4642-AF58-4873234031B0Q39355333-F63F6917-B79B-46C6-A635-2988CD105B47Q40371860-C3B40061-BF27-49D8-8C36-9B43991D7A93Q47960232-8D8D3F81-489B-4ABC-9FBE-04EC0133B419Q50057798-6BDE76C1-35AA-45FA-88F5-9D8493FE1D64Q50167649-29C6226B-1A0E-4A9A-B371-D8A9E6422BB9Q52655331-4392C560-7869-48DD-94AD-C0FFAB4559BEQ53091285-2404129C-ACFE-45F4-9327-F86848B4CD53Q55399780-AF66BECB-04D8-4C01-A993-77C7EBBEFF95Q55713330-372753F0-0169-4DEE-9F94-A263008E4D96Q57180908-C6D23FC0-1BF3-4F4B-8C0E-E007C3B02C49Q64097119-142E9301-45C8-490B-AA1A-9AFEF4B87D8CQ83945745-406CEA60-F766-4519-9AB7-74AB4A1B227FQ89826994-AEF8D558-B561-4AFA-909D-F88C448FFDA0Q89969328-D92E98B9-5AC3-4B00-9948-3EDEBCE64182Q90727301-885E1111-63F4-4DC7-930F-D09D100F59F7Q91431441-13B8B8A1-685F-4789-A8E3-EB0470824701Q91562188-8DF1614E-8660-4C5D-90A8-99F543A4CB16Q92111026-6B50F058-6359-4AC6-8743-2B84816EE82DQ92529481-472DA656-03EE-42E0-9A71-0D0204D01839Q92670188-B39F856E-0FF3-4F85-8343-0F47BAB94625Q92926639-27922667-CB1A-4B67-B511-A089CC2D744A
P50
description
researcher ORCID ID = 0000-0001-7184-9165
@en
wetenschapper
@nl
name
Helena Kopp Kallner
@ast
Helena Kopp Kallner
@en
Helena Kopp Kallner
@es
Helena Kopp Kallner
@nl
type
label
Helena Kopp Kallner
@ast
Helena Kopp Kallner
@en
Helena Kopp Kallner
@es
Helena Kopp Kallner
@nl
prefLabel
Helena Kopp Kallner
@ast
Helena Kopp Kallner
@en
Helena Kopp Kallner
@es
Helena Kopp Kallner
@nl
P106
P21
P31
P496
0000-0001-7184-9165